Amended Current Report Filing (8-k/a)
July 18 2017 - 6:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 11, 2017
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
1-16467
|
|
33-0303583
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S
Employer
Identification No.)
|
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Explanatory
Note
This
Amendment No. 1 amends the Current Report on Form 8-K filed by RespireRx Pharmaceuticals Inc. (the “Company”) on July
11, 2017 (the “Original Form 8-K”) solely to correct the Ampakine Executive Summary furnished as Exhibit 99.3 thereto
(the “Exhibit”). As previously furnished, the Exhibit inadvertently did not include certain attribution information
for some of the material presented therein; this has been corrected in the version of the Exhibit furnished with this Amendment
No. 1. No other changes have been made to the Original Form 8-K.
Item
7.01 Regulation FD Disclosure
Exhibit
99.3 attached hereto replaces Exhibits 99.3 furnished on the Original Form 8-K. The foregoing information is furnished pursuant
to Item 7.01 Regulation FD Disclosure and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act
of 1934 (as amended, the “Exchange Act”) or incorporated by reference into any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished as part of this report is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
July 17, 2017
|
RESPIRERX
PHARMACEUTICALS INC.
|
|
|
|
|
|
|
By:
|
/s/
Jeff E. Margolis
|
|
|
|
Jeff
E. Margolis
Senior
Vice President, CFO, Treasurer and Secretary
|
EXHIBIT
INDEX
|
Exhibit
Number
|
|
Exhibit
Description
|
|
|
|
|
|
99.3
|
|
Ampakine
Executive Summary*
|
*
Furnished herewith.
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024
